Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 125 entries
Sorted by: Best Match Show Resources per page
Patient involvement in guidelines is poor five years after institute of medicine standards: review of guideline methodologies.

Research involvement and engagement

Armstrong MJ, Bloom JA.
PMID: 29062544
Res Involv Engagem. 2017 Oct 02;3:19. doi: 10.1186/s40900-017-0070-2. eCollection 2017.

BACKGROUND: The United States-based Institute of Medicine 2011 standards for trustworthy clinical practice guideline development recommended patient and public involvement in guideline development via participation by patients and public representatives on guideline development groups and via external review and...

Cite
Armstrong MJ, Bloom JA. Patient involvement in guidelines is poor five years after institute of medicine standards: review of guideline methodologies. Res Involv Engagem. 2017;3:19doi: 10.1186/s40900-017-0070-2.
Armstrong, M. J., & Bloom, J. A. (2017). Patient involvement in guidelines is poor five years after institute of medicine standards: review of guideline methodologies. Research involvement and engagement, 319. https://doi.org/10.1186/s40900-017-0070-2
Armstrong, Melissa J, and Bloom, Joshua A. "Patient involvement in guidelines is poor five years after institute of medicine standards: review of guideline methodologies." Research involvement and engagement vol. 3 (2017): 19. doi: https://doi.org/10.1186/s40900-017-0070-2
Armstrong MJ, Bloom JA. Patient involvement in guidelines is poor five years after institute of medicine standards: review of guideline methodologies. Res Involv Engagem. 2017 Oct 02;3:19. doi: 10.1186/s40900-017-0070-2. eCollection 2017. PMID: 29062544; PMCID: PMC5623959.
Copy Download .nbib Format: NLM
Magnetic Resonance Q Mapping Reveals a Decrease in Microvessel Density in the arcAβ Mouse Model of Cerebral Amyloidosis.

Frontiers in aging neuroscience

Ielacqua GD, Schlegel F, Füchtemeier M, Xandry J, Rudin M, Klohs J.
PMID: 26834622
Front Aging Neurosci. 2016 Jan 19;7:241. doi: 10.3389/fnagi.2015.00241. eCollection 2015.

Alterations in density and morphology of the cerebral microvasculature have been reported to occur in Alzheimer's disease patients and animal models of the disease. In this study we compared magnetic resonance imaging (MRI) techniques for their utility to detect...

Cite
Ielacqua GD, Schlegel F, Füchtemeier M, et al. Magnetic Resonance Q Mapping Reveals a Decrease in Microvessel Density in the arcAβ Mouse Model of Cerebral Amyloidosis. Front Aging Neurosci. 2016;7:241doi: 10.3389/fnagi.2015.00241.
Ielacqua, G. D., Schlegel, F., Füchtemeier, M., Xandry, J., Rudin, M., & Klohs, J. (2015). Magnetic Resonance Q Mapping Reveals a Decrease in Microvessel Density in the arcAβ Mouse Model of Cerebral Amyloidosis. Frontiers in aging neuroscience, 7241. https://doi.org/10.3389/fnagi.2015.00241
Ielacqua, Giovanna D, et al. "Magnetic Resonance Q Mapping Reveals a Decrease in Microvessel Density in the arcAβ Mouse Model of Cerebral Amyloidosis." Frontiers in aging neuroscience vol. 7 (2015): 241. doi: https://doi.org/10.3389/fnagi.2015.00241
Ielacqua GD, Schlegel F, Füchtemeier M, Xandry J, Rudin M, Klohs J. Magnetic Resonance Q Mapping Reveals a Decrease in Microvessel Density in the arcAβ Mouse Model of Cerebral Amyloidosis. Front Aging Neurosci. 2016 Jan 19;7:241. doi: 10.3389/fnagi.2015.00241. eCollection 2015. PMID: 26834622; PMCID: PMC4717293.
Copy Download .nbib Format: NLM
Correction: Metformin exhibits preventive and therapeutic efficacy against experimental cystic echinococcosis.

PLoS neglected tropical diseases

Loos JA, Dávila VA, Rodriguez Rodrigues C, Petrigh R, Zoppi JA, Crocenzi FA, Cumino AC.
PMID: 28328970
PLoS Negl Trop Dis. 2017 Mar 22;11(3):e0005474. doi: 10.1371/journal.pntd.0005474. eCollection 2017 Mar.

[This corrects the article DOI: 10.1371/journal.pntd.0005370.].

Cite
Loos JA, Dávila VA, Rodriguez Rodrigues C, et al. Correction: Metformin exhibits preventive and therapeutic efficacy against experimental cystic echinococcosis. PLoS Negl Trop Dis. 2017;11(3):e0005474doi: 10.1371/journal.pntd.0005474.
Loos, J. A., Dávila, V. A., Rodriguez Rodrigues, C., Petrigh, R., Zoppi, J. A., Crocenzi, F. A., & Cumino, A. C. (2017). Correction: Metformin exhibits preventive and therapeutic efficacy against experimental cystic echinococcosis. PLoS neglected tropical diseases, 11(3), e0005474. https://doi.org/10.1371/journal.pntd.0005474
Loos, Julia A, et al. "Correction: Metformin exhibits preventive and therapeutic efficacy against experimental cystic echinococcosis." PLoS neglected tropical diseases vol. 11,3 (2017): e0005474. doi: https://doi.org/10.1371/journal.pntd.0005474
Loos JA, Dávila VA, Rodriguez Rodrigues C, Petrigh R, Zoppi JA, Crocenzi FA, Cumino AC. Correction: Metformin exhibits preventive and therapeutic efficacy against experimental cystic echinococcosis. PLoS Negl Trop Dis. 2017 Mar 22;11(3):e0005474. doi: 10.1371/journal.pntd.0005474. eCollection 2017 Mar. PMID: 28328970; PMCID: PMC5362040.
Copy Download .nbib Format: NLM
DNA Isolation and GC Base Composition of Four Root-knot Nematode (Meloidogyne spp.) Genomes.

Journal of nematology

Pableo EC, Triantaphyllou AC, Kloos WE.
PMID: 19290179
J Nematol. 1988 Jan;20(1):1-8.

Phenol extraction and cesium trifluoroacetate ultracentrifugation were compared for efficiency in the extraction of DNA from eggs and second-stage juveniles of four species of Meloidogyne. The second method proved to be more satisfactory in that it yielded larger amounts...

Cite
Pableo EC, Triantaphyllou AC, Kloos WE. DNA Isolation and GC Base Composition of Four Root-knot Nematode (Meloidogyne spp.) Genomes. J Nematol. 1988;20(1):1-8
Pableo, E. C., Triantaphyllou, A. C., & Kloos, W. E. (1988). DNA Isolation and GC Base Composition of Four Root-knot Nematode (Meloidogyne spp.) Genomes. Journal of nematology, 20(1), 1-8.
Pableo, E C, et al. "DNA Isolation and GC Base Composition of Four Root-knot Nematode (Meloidogyne spp.) Genomes." Journal of nematology vol. 20,1 (1988): 1-8.
Pableo EC, Triantaphyllou AC, Kloos WE. DNA Isolation and GC Base Composition of Four Root-knot Nematode (Meloidogyne spp.) Genomes. J Nematol. 1988 Jan;20(1):1-8. PMID: 19290179; PMCID: PMC2618780.
Copy Download .nbib Format: NLM
Glycogen storage disease type II: birth prevalence agrees with predicted genotype frequency.

Community genetics

Ausems MG, ten Berg K, Kroos MA, van Diggelen OP, Wevers RA, Poorthuis BJ, Niezen-Koning KE, van der Ploeg AT, Beemer FA, Reuser AJ, Sandkuijl LA, Wokke JH.
PMID: 15181339
Community Genet. 1999;2(2):91-6. doi: 10.1159/000016192.

OBJECTIVES: To compare the overall birth prevalence of diagnosed glycogen storage disease type II (GSD II) with the predicted frequency based on mutation screening, in order to determine whether GSD II is an underdiagnosed condition, and to analyze which...

Cite
Ausems MG, ten Berg K, Kroos MA, et al. Glycogen storage disease type II: birth prevalence agrees with predicted genotype frequency. Community Genet. 1999;2(2):91-6doi: 10.1159/000016192.
Ausems, M. G., ten Berg, K., Kroos, M. A., van Diggelen, O. P., Wevers, R. A., Poorthuis, B. J., Niezen-Koning, K. E., van der Ploeg, A. T., Beemer, F. A., Reuser, A. J., Sandkuijl, L. A., & Wokke, J. H. (1999). Glycogen storage disease type II: birth prevalence agrees with predicted genotype frequency. Community genetics, 2(2), 91-6. https://doi.org/10.1159/000016192
Ausems, M G, et al. "Glycogen storage disease type II: birth prevalence agrees with predicted genotype frequency." Community genetics vol. 2,2 (1999): 91-6. doi: https://doi.org/10.1159/000016192
Ausems MG, ten Berg K, Kroos MA, van Diggelen OP, Wevers RA, Poorthuis BJ, Niezen-Koning KE, van der Ploeg AT, Beemer FA, Reuser AJ, Sandkuijl LA, Wokke JH. Glycogen storage disease type II: birth prevalence agrees with predicted genotype frequency. Community Genet. 1999;2(2):91-6. doi: 10.1159/000016192. PMID: 15181339.
Copy Download .nbib Format: NLM
Models to predict positive and negative effects of cochlear implantation on tinnitus.

Laryngoscope investigative otolaryngology

Kloostra FJJ, Arnold R, Hofman R, Burgerhof JGM, van Dijk P.
PMID: 30828631
Laryngoscope Investig Otolaryngol. 2018 Dec 14;4(1):138-142. doi: 10.1002/lio2.224. eCollection 2019 Feb.

OBJECTIVES: The effect of cochlear implantation on tinnitus is heterogeneous: implantation does not always reduce tinnitus and may even worsen tinnitus. Therefore, it is important to know which factors influence the consequences of cochlear implantation for tinnitus. To date,...

Cite
Kloostra FJJ, Arnold R, Hofman R, et al. Models to predict positive and negative effects of cochlear implantation on tinnitus. Laryngoscope Investig Otolaryngol. 2018;4(1):138-142doi: 10.1002/lio2.224.
Kloostra, F. J. J., Arnold, R., Hofman, R., Burgerhof, J. G. M., & van Dijk, P. (2019). Models to predict positive and negative effects of cochlear implantation on tinnitus. Laryngoscope investigative otolaryngology, 4(1), 138-142. https://doi.org/10.1002/lio2.224
Kloostra, F J J, et al. "Models to predict positive and negative effects of cochlear implantation on tinnitus." Laryngoscope investigative otolaryngology vol. 4,1 (2019): 138-142. doi: https://doi.org/10.1002/lio2.224
Kloostra FJJ, Arnold R, Hofman R, Burgerhof JGM, van Dijk P. Models to predict positive and negative effects of cochlear implantation on tinnitus. Laryngoscope Investig Otolaryngol. 2018 Dec 14;4(1):138-142. doi: 10.1002/lio2.224. eCollection 2019 Feb. PMID: 30828631; PMCID: PMC6383300.
Copy Download .nbib Format: NLM
Patient-reported outcome measures after 8 weeks of mepolizumab treatment and long-term outcomes in patients with severe asthma: an observational study.

International journal of clinical pharmacy

Kroes JA, Zielhuis SW, van der Meer AN, de Jong K, Ten Brinke A, van Roon EN.
PMID: 34851505
Int J Clin Pharm. 2021 Dec 01; doi: 10.1007/s11096-021-01362-8. Epub 2021 Dec 01.

Background The novel anti-IL-5 drug mepolizumab improves asthma outcomes in the majority but not all patients with severe eosinophilic asthma. Currently it is difficult to predict an individuals' chance of being a responder. Early changes in patient-reported outcome measures...

Cite
Kroes JA, Zielhuis SW, van der Meer AN, et al. Patient-reported outcome measures after 8 weeks of mepolizumab treatment and long-term outcomes in patients with severe asthma: an observational study. Int J Clin Pharm. 2021;doi: 10.1007/s11096-021-01362-8.
Kroes, J. A., Zielhuis, S. W., van der Meer, A. N., de Jong, K., Ten Brinke, A., & van Roon, E. N. (2021). Patient-reported outcome measures after 8 weeks of mepolizumab treatment and long-term outcomes in patients with severe asthma: an observational study. International journal of clinical pharmacy, . https://doi.org/10.1007/s11096-021-01362-8
Kroes, Johannes Anthon, et al. "Patient-reported outcome measures after 8 weeks of mepolizumab treatment and long-term outcomes in patients with severe asthma: an observational study." International journal of clinical pharmacy vol. (2021). doi: https://doi.org/10.1007/s11096-021-01362-8
Kroes JA, Zielhuis SW, van der Meer AN, de Jong K, Ten Brinke A, van Roon EN. Patient-reported outcome measures after 8 weeks of mepolizumab treatment and long-term outcomes in patients with severe asthma: an observational study. Int J Clin Pharm. 2021 Dec 01; doi: 10.1007/s11096-021-01362-8. Epub 2021 Dec 01. PMID: 34851505.
Copy Download .nbib Format: NLM
CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment.

Cell reports

Klomp JE, Lee YS, Goodwin CM, Papke B, Klomp JA, Waters AM, Stalnecker CA, DeLiberty JM, Drizyte-Miller K, Yang R, Diehl JN, Yin HH, Pierobon M, Baldelli E, Ryan MB, Li S, Peterson J, Smith AR, Neal JT, McCormick AK, Kuo CJ, Counter CM, Petricoin EF, Cox AD, Bryant KL, Der CJ.
PMID: 34852220
Cell Rep. 2021 Nov 30;37(9):110060. doi: 10.1016/j.celrep.2021.110060.

We apply genetic screens to delineate modulators of KRAS mutant pancreatic ductal adenocarcinoma (PDAC) sensitivity to ERK inhibitor treatment, and we identify components of the ATR-CHK1 DNA damage repair (DDR) pathway. Pharmacologic inhibition of CHK1 alone causes apoptotic growth...

Cite
Klomp JE, Lee YS, Goodwin CM, et al. CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment. Cell Rep. 2021;37(9):110060doi: 10.1016/j.celrep.2021.110060.
Klomp, J. E., Lee, Y. S., Goodwin, C. M., Papke, B., Klomp, J. A., Waters, A. M., Stalnecker, C. A., DeLiberty, J. M., Drizyte-Miller, K., Yang, R., Diehl, J. N., Yin, H. H., Pierobon, M., Baldelli, E., Ryan, M. B., Li, S., Peterson, J., Smith, A. R., Neal, J. T., McCormick, A. K., Kuo, C. J., Counter, C. M., Petricoin, E. F., Cox, A. D., Bryant, K. L., & Der, C. J. (2021). CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment. Cell reports, 37(9), 110060. https://doi.org/10.1016/j.celrep.2021.110060
Klomp, Jennifer E, et al. "CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment." Cell reports vol. 37,9 (2021): 110060. doi: https://doi.org/10.1016/j.celrep.2021.110060
Klomp JE, Lee YS, Goodwin CM, Papke B, Klomp JA, Waters AM, Stalnecker CA, DeLiberty JM, Drizyte-Miller K, Yang R, Diehl JN, Yin HH, Pierobon M, Baldelli E, Ryan MB, Li S, Peterson J, Smith AR, Neal JT, McCormick AK, Kuo CJ, Counter CM, Petricoin EF, Cox AD, Bryant KL, Der CJ. CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment. Cell Rep. 2021 Nov 30;37(9):110060. doi: 10.1016/j.celrep.2021.110060. PMID: 34852220; PMCID: PMC8665414.
Copy Download .nbib Format: NLM
Molecular Dynamics in Nanocomposites Based on Renewable Poly(butylene 2,5-furan-dicarboxylate) In Situ Reinforced by Montmorillonite Nanoclays: Effects of Clay Modification, Crystallization, and Hydration.

The journal of physical chemistry. B

Klonos PA, Papadopoulos L, Terzopoulou Z, Papageorgiou GZ, Kyritsis A, Bikiaris DN.
PMID: 32786716
J Phys Chem B. 2020 Aug 20;124(33):7306-7317. doi: 10.1021/acs.jpcb.0c04306. Epub 2020 Aug 07.

This study deals with poly(butylene 2,5-furan-dicarboxylate), PBF, a renewable bio-based polyester expected to replace non-eco-friendly fossil-based homologues. PBF exhibits excellent gas barrier properties, which makes it promising for packaging applications; however, its rather low and slow crystallinity affects good...

Cite
Klonos PA, Papadopoulos L, Terzopoulou Z, et al. Molecular Dynamics in Nanocomposites Based on Renewable Poly(butylene 2,5-furan-dicarboxylate) In Situ Reinforced by Montmorillonite Nanoclays: Effects of Clay Modification, Crystallization, and Hydration. J Phys Chem B. 2020;124(33):7306-7317doi: 10.1021/acs.jpcb.0c04306.
Klonos, P. A., Papadopoulos, L., Terzopoulou, Z., Papageorgiou, G. Z., Kyritsis, A., & Bikiaris, D. N. (2020). Molecular Dynamics in Nanocomposites Based on Renewable Poly(butylene 2,5-furan-dicarboxylate) In Situ Reinforced by Montmorillonite Nanoclays: Effects of Clay Modification, Crystallization, and Hydration. The journal of physical chemistry. B, 124(33), 7306-7317. https://doi.org/10.1021/acs.jpcb.0c04306
Klonos, Panagiotis A, et al. "Molecular Dynamics in Nanocomposites Based on Renewable Poly(butylene 2,5-furan-dicarboxylate) In Situ Reinforced by Montmorillonite Nanoclays: Effects of Clay Modification, Crystallization, and Hydration." The journal of physical chemistry. B vol. 124,33 (2020): 7306-7317. doi: https://doi.org/10.1021/acs.jpcb.0c04306
Klonos PA, Papadopoulos L, Terzopoulou Z, Papageorgiou GZ, Kyritsis A, Bikiaris DN. Molecular Dynamics in Nanocomposites Based on Renewable Poly(butylene 2,5-furan-dicarboxylate) In Situ Reinforced by Montmorillonite Nanoclays: Effects of Clay Modification, Crystallization, and Hydration. J Phys Chem B. 2020 Aug 20;124(33):7306-7317. doi: 10.1021/acs.jpcb.0c04306. Epub 2020 Aug 07. PMID: 32786716.
Copy Download .nbib Format: NLM
The challenges of identifying and classifying child sexual exploitation material: Moving towards a more ecologically valid pilot study with digital forensics analysts.

Child abuse & neglect

Kloess JA, Woodhams J, Hamilton-Giachritsis CE.
PMID: 34153578
Child Abuse Negl. 2021 Aug;118:105166. doi: 10.1016/j.chiabu.2021.105166. Epub 2021 Jun 18.

BACKGROUND: When child sexual exploitation material is seized, digital forensics analysts are required to manually process all "unknown" digital material by determining (a) whether a child is present in the image, and (b) whether the image is of an...

Cite
Kloess JA, Woodhams J, Hamilton-Giachritsis CE. The challenges of identifying and classifying child sexual exploitation material: Moving towards a more ecologically valid pilot study with digital forensics analysts. Child Abuse Negl. 2021;118:105166doi: 10.1016/j.chiabu.2021.105166.
Kloess, J. A., Woodhams, J., & Hamilton-Giachritsis, C. E. (2021). The challenges of identifying and classifying child sexual exploitation material: Moving towards a more ecologically valid pilot study with digital forensics analysts. Child abuse & neglect, 118105166. https://doi.org/10.1016/j.chiabu.2021.105166
Kloess, Juliane A, et al. "The challenges of identifying and classifying child sexual exploitation material: Moving towards a more ecologically valid pilot study with digital forensics analysts." Child abuse & neglect vol. 118 (2021): 105166. doi: https://doi.org/10.1016/j.chiabu.2021.105166
Kloess JA, Woodhams J, Hamilton-Giachritsis CE. The challenges of identifying and classifying child sexual exploitation material: Moving towards a more ecologically valid pilot study with digital forensics analysts. Child Abuse Negl. 2021 Aug;118:105166. doi: 10.1016/j.chiabu.2021.105166. Epub 2021 Jun 18. PMID: 34153578.
Copy Download .nbib Format: NLM
Picomolar FKBP inhibitors enabled by a single water-displacing methyl group in bicyclic [4.3.1] aza-amides.

Chemical science

Kolos JM, Pomplun S, Jung S, Rieß B, Purder PL, Voll AM, Merz S, Gnatzy M, Geiger TM, Quist-Løkken I, Jatzlau J, Knaus P, Holien T, Bracher A, Meyners C, Czodrowski P, Krewald V, Hausch F.
PMID: 34820091
Chem Sci. 2021 Nov 03;12(44):14758-14765. doi: 10.1039/d1sc04638a. eCollection 2021 Nov 17.

Methyl groups can have profound effects in drug discovery but the underlying mechanisms are diverse and incompletely understood. Here we report the stereospecific effect of a single, solvent-exposed methyl group in bicyclic [4.3.1] aza-amides, robustly leading to a 2...

Cite
Kolos JM, Pomplun S, Jung S, et al. Picomolar FKBP inhibitors enabled by a single water-displacing methyl group in bicyclic [4.3.1] aza-amides. Chem Sci. 2021;12(44):14758-14765doi: 10.1039/d1sc04638a.
Kolos, J. M., Pomplun, S., Jung, S., Rieß, B., Purder, P. L., Voll, A. M., Merz, S., Gnatzy, M., Geiger, T. M., Quist-Løkken, I., Jatzlau, J., Knaus, P., Holien, T., Bracher, A., Meyners, C., Czodrowski, P., Krewald, V., & Hausch, F. (2021). Picomolar FKBP inhibitors enabled by a single water-displacing methyl group in bicyclic [4.3.1] aza-amides. Chemical science, 12(44), 14758-14765. https://doi.org/10.1039/d1sc04638a
Kolos, Jürgen M, et al. "Picomolar FKBP inhibitors enabled by a single water-displacing methyl group in bicyclic [4.3.1] aza-amides." Chemical science vol. 12,44 (2021): 14758-14765. doi: https://doi.org/10.1039/d1sc04638a
Kolos JM, Pomplun S, Jung S, Rieß B, Purder PL, Voll AM, Merz S, Gnatzy M, Geiger TM, Quist-Løkken I, Jatzlau J, Knaus P, Holien T, Bracher A, Meyners C, Czodrowski P, Krewald V, Hausch F. Picomolar FKBP inhibitors enabled by a single water-displacing methyl group in bicyclic [4.3.1] aza-amides. Chem Sci. 2021 Nov 03;12(44):14758-14765. doi: 10.1039/d1sc04638a. eCollection 2021 Nov 17. PMID: 34820091; PMCID: PMC8597852.
Copy Download .nbib Format: NLM
Low Molecular Weight Oligomers of Poly(alkylene succinate) Polyesters as Plasticizers in Poly(vinyl alcohol) Based Pharmaceutical Applications.

Polymers

Palamidi A, Kapourani A, Christodoulou E, Klonos PA, Kontogiannopoulos KN, Kyritsis A, Bikiaris DN, Barmpalexis P.
PMID: 33401411
Polymers (Basel). 2021 Jan 01;13(1). doi: 10.3390/polym13010146.

The plasticizing effect of three low molecular weight oligomers of aliphatic poly(alkylene succinate) polyesters, namely poly(butylene succinate) (PBSu), poly(ethylene succinate) (PESu), and poly(propylene succinate) (PPSu), on partially hydrolyzed poly(vinyl alcohol) (PVA) used in melt-based pharmaceutical applications, was evaluated for...

Cite
Palamidi A, Kapourani A, Christodoulou E, et al. Low Molecular Weight Oligomers of Poly(alkylene succinate) Polyesters as Plasticizers in Poly(vinyl alcohol) Based Pharmaceutical Applications. Polymers (Basel). 2021;13(1)doi: 10.3390/polym13010146.
Palamidi, A., Kapourani, A., Christodoulou, E., Klonos, P. A., Kontogiannopoulos, K. N., Kyritsis, A., Bikiaris, D. N., & Barmpalexis, P. (2021). Low Molecular Weight Oligomers of Poly(alkylene succinate) Polyesters as Plasticizers in Poly(vinyl alcohol) Based Pharmaceutical Applications. Polymers, 13(1), . https://doi.org/10.3390/polym13010146
Palamidi, Artemis, et al. "Low Molecular Weight Oligomers of Poly(alkylene succinate) Polyesters as Plasticizers in Poly(vinyl alcohol) Based Pharmaceutical Applications." Polymers vol. 13,1 (2021). doi: https://doi.org/10.3390/polym13010146
Palamidi A, Kapourani A, Christodoulou E, Klonos PA, Kontogiannopoulos KN, Kyritsis A, Bikiaris DN, Barmpalexis P. Low Molecular Weight Oligomers of Poly(alkylene succinate) Polyesters as Plasticizers in Poly(vinyl alcohol) Based Pharmaceutical Applications. Polymers (Basel). 2021 Jan 01;13(1). doi: 10.3390/polym13010146. PMID: 33401411; PMCID: PMC7795009.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 125 entries